ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025
Rectal colonization with multidrug-resistant organisms and risk for bloodstream infection among high-risk Greek patients.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Risk factors associated with the development of multidrug-resistant bloodstream infection in patients with colonization: a case-control retrospective study.IJID regions · 2026Article
- Unveiling the role of sex as a predictor for KPC-Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii bacteremia in critically Ill colonized patients.BMC infectious diseases · 2026Article
- Temporal dynamics and predictors of carbapenem-resistant gram-negative bacteria in bloodstream infections in hematological patients.BMC infectious diseases · 2026Article
- The Role of Routine Surveillance Cultures in Optimising Sepsis Management in High-Risk Patient Groups.Pathogens (Basel, Switzerland) · 2026Article
- Epidemiological Situation of Antibiotic-Resistant Microorganisms Identified in Patients Hospitalised at the University Teaching Hospital in Bialystok, Poland, in the 2020-2023 Period.Antibiotics (Basel, Switzerland) · 2025Article
- Update on infection prevention in the ICU.Current opinion in critical care · 2025Review
- From Colonisation to Infection: Assessing the BSI Potential in Patients with KPC, NDM, VRE and CRAB Rectal Colonisation.Infectious diseases and therapy · 2025Article
- Vancomycin-Resistant Enterococci: Screening Efficacy and the Risk of Bloodstream Infections in a Specialized Healthcare Setting.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies link multidrug-resistant organism (MDRO) rectal colonization to increased infection risk, data from Greece, a country with high rates of MDRO, are limited.
methodsWe assessed bloodstream infection (BSI) risk following rectal colonization by MDROs across three Greek hospitals (2019-2022).
resultsOf 4,370 inpatients, 31.1% were colonized by carbapenem-resistant Enterobacterales (CRE), 30.1% carbapenem-resistant Acinetobacter baumannii (CRAB), 5.8% carbapenem-resistant Pseudomonas aeruginosa (CRPA), 28.4% vancomycin-resistant enterococci (VRE). Subsequent BSI from the same MDRO species was developed in 15.6% of CRE, 19.7% of CRAB, 9.2% of CRPA and 3.5% of VRE carriers. Previous rectal colonization increases significantly MDRO BSI risk [RR (95%CI): CRE 5.2 (3.9-6.8), CRAB 2.7 (2.2-3.3), CRPA 9.6 (5.8-16.0), VRE 2.5 (1.5-4.2)].
conclusionClinicians should consider MDRO carriage information for selecting empiric treatment.
Indexed as
Identifiers
39572409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.